Cambridge Enterprise licenses cholangiocyte stem cell technology to DefiniGEN
DefiniGEN, a leading provider of stem cell products and services, has announced that it has strengthened its IP portfolio with a licence for cutting-edge cholangiocyte liver technology from Cambridge Enterprise, the commercialisation arm of the University of Cambridge. The technology will be used by DefiniGEN to develop optimised liver cell products and services for various applications such as disease modelling, drug screening and therapeutic target validation. Cholangiocytes are specialised liver cells that form the bile duct. Diseases of these cells are responsible for 30 per cent of all liver transplants.
Read the full press release here.
Mewburn Ellis partner Nick Sutcliffe prepared patent applications covering this technology for Cambridge Enterprise and continues to work closely with Cambridge Enterprise to prepare and file patent applications and manage their IP portfolio.